Aastrom Biosciences Announces Appointment of Joyce L. Frey-Vasconcells, Ph.D. to Scientific Advisory Board
29 oct. 2012 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Oct. 29, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences CEO Tim M. Mayleben Announces Plan to Retire
04 oct. 2012 16h01 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Oct. 4, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom to Participate in Noble Financial Capital Markets' BioX Life Sciences Exposition
19 sept. 2012 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 19, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Appoints Daniel R. Orlando as Chief Commercial Officer
05 sept. 2012 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 5, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Reports Operating Results for the Quarter and Six Months Ended June 30, 2012
07 août 2012 16h01 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe...
Aastrom to Host Second Quarter 2012 Investor Call on August 7, 2012
02 août 2012 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Announces Results of Common Stock Exchange for December 2010 Warrants
30 juil. 2012 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., July 30, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Announces Common Stock Exchange for December 2010 Warrants
27 juin 2012 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., June 27, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Ixmyelocel-T Shown to Protect Heart From Damage in Murine Model of Heart Failure
06 juin 2012 18h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., June 6, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Present at World Stem Cells & Regenerative Medicine Congress
17 mai 2012 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., May 17, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...